This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Valvoline (VVV) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Valvoline (VVV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ingevity's (NGVT) Earnings and Sales Beat Estimates in Q1
by Zacks Equity Research
Ingevity (NGVT) benefits from higher demand across its businesses in the first quarter.
Ingevity (NGVT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 18.69% and 9.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Ingevity (NGVT) Adds Caprolactone Polyol Production at DeRidder
by Zacks Equity Research
Ingevity's (NGVT) latest addition to production capabilities will enable it to cater to increasing demand for Capa suite of technologies.
Ingevity (NGVT) Expands Production Capacity at Zhuhai Plant
by Zacks Equity Research
Ingevity's (NGVT) plant upgrades help increase its capacity and enable it to serve global demand for premium carbon products.
Ingevity's (NGVT) Earnings and Sales Top Estimates in Q4
by Zacks Equity Research
Ingevity (NGVT) benefits from higher demand for engineered polymers and a recovery of global automotive production in Q4.
Ingevity (NGVT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 95.59% and 16.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ingevity (NGVT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ingevity (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ingevity's (NGVT) Shares Gain 27% in 6 Months: Here's Why
by Zacks Equity Research
Ingevity (NGVT) gains on regulation-driven adoption of its applications and cost-cutting actions.
Ingevity (NGVT) Stock Up 15% in 3 Months: What's Driving It?
by Zacks Equity Research
Ingevity (NGVT) benefits from its cost actions, Capa acquisition and growth in its applications driven by regulations and technology adoption.
Venator (VNTR) Surges: Stock Moves 6.9% Higher
by Zacks Equity Research
Venator (VNTR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
4 Chemical Specialty Stocks to Escape Industry Challenges
by Anindya Barman
Soft demand amid sluggish industrial activities due to coronavirus clouds prospects for the Zacks Chemicals Specialty industry. Quaker Chemical (KWR), Valvoline (VVV), Element Solutions (ESI) and Ingevity (NGVT) are set to gain from self-help actions.
Ingevity (NGVT) Up 12% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why You Should Add Ingevity (NGVT) Stock to Your Portfolio
by Zacks Equity Research
Ingevity (NGVT) benefits from regulation-driven adoption of its applications and cost-reduction measures.
Ingevity (NGVT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 82.65% and 6.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ingevity (NGVT) Up 44% in 6 Months: What's Behind the Rally?
by Zacks Equity Research
Ingevity (NGVT) benefits from its cost-management actions and regulation-driven demand for its applications.
Ingevity Gains on Cost Actions Amid Weak Industrial Demand
by Anindya Barman
Ingevity (NGVT) benefits from cost-reduction measures and growth in its applications driven by regulations and technology adoption.
Why You Should Keep Ingevity (NGVT) Stock in Your Portfolio
by Zacks Equity Research
While Ingevity (NGVT) faces headwind from soft demand in industrial specialties and oilfield technologies, it should gain from cost actions and regulation-driven adoption of its applications.
Ingevity (NGVT) Up 57% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Ingevity (NGVT) benefits from its cost-saving actions and growth in its applications driven by regulations and technology adoption.
Why Is Ingevity Corporation (NGVT) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto Ingevity (NGVT) Stock for Now
by Zacks Equity Research
While Ingevity (NGVT) is exposed to weakness in industrial specialties and oilfield technologies businesses, it should gain from strong demand for activated carbon products in China and cost actions.
Ingevity (NGVT) Earnings Meet, Sales Beat Estimates in Q2
by Zacks Equity Research
Ingevity's (NGVT) Q2 revenues decline year over year on account of weaker demand, fuelled by the economic impacts of the coronavirus pandemic.
Ingevity Corporation (NGVT) Matches Q2 Earnings Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 0.00% and 7.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ingevity Corporation (NGVT) Q2 Earnings Expected to Decline
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemical Specialty Industry Outlook Bleak on Muted Demand
by Anindya Barman
Weak demand and raw material supply disruptions due to coronavirus pose as headwinds to the chemical specialty industry.